Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections

New Partnership to Jointly Conduct Preclinical Development of
Cidara’s Cloudbreak Antibody-Drug Conjugates

SAN DIEGO–(BUSINESS WIRE)–May 21, 2018–
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that it and Rutgers University have been awarded a five-year,
$5.5 million partnership grant from the U.S. National Institute of
Allergy and Infectious Diseases (NIAID) of the National Institutes of
Health (NIH), an agency of the United States Department of Health and
Human Services.

The grant will fund the continued researc…

READ FULL TEXT

Leave a Reply

Your email address will not be published.